Prestige Consumer (NYSE: PBH) shares Q3 and nine‑month results

Rhea-AI Filing Summary

Prestige Consumer Healthcare Inc. filed a current report to share that it has announced financial results for the fiscal quarter and nine months ended December 31, 2025. The detailed numbers are provided in a separate earnings press release attached as Exhibit 99.1.

The company is also using an investor presentation, attached as Exhibit 99.2, to discuss these results with investors, analysts and others during the fiscal year ending March 31, 2026. Both the press release and presentation are being treated as “furnished,” meaning they are provided for information and are not classified as formally filed financial statements under securities laws.

0001295947false00012959472026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 5, 2026

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-32433

20-1297589

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

660 White Plains Road, Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, par value $0.01 per share			PBH			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 2.02 Results of Operations and Financial Condition.

On February 5, 2026, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and nine months ended December 31, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter and nine months ended December 31, 2025 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On February 5, 2026, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and nine months ended December 31, 2025 using slides attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”) and incorporated herein by reference.  The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2026.

By furnishing the information contained in this Item 7.01, the Company makes no admission as to the materiality of any information that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits.

See Exhibit Index immediately following the signature page.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 5, 2026			PRESTIGE CONSUMER HEALTHCARE INC.
			By:			/s/ Christine Sacco
						Christine Sacco
						Chief Financial Officer & Chief Operating Officer

EXHIBIT INDEX

 

Exhibit						Description
99.1						Press Release dated February 5, 2026, announcing the Company's financial results for the fiscal quarter and nine months ended December 31, 2025 (furnished only).
99.2						Investor Presentation in use beginning February 5, 2026 (furnished only).
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

FAQ

What did Prestige Consumer Healthcare (PBH) announce in this 8-K?

Prestige Consumer Healthcare announced that it has released financial results for the fiscal quarter and nine months ended December 31, 2025. The specific figures are contained in an attached press release (Exhibit 99.1) rather than directly in this report’s main text.

Where can investors find Prestige Consumer Healthcare’s Q3 2025 financial details?

Investors can find the detailed financial results in the press release attached as Exhibit 99.1. This document contains the company’s earnings information for the fiscal quarter and nine months ended December 31, 2025, and is incorporated by reference in the current report.

What is included in Prestige Consumer Healthcare’s investor presentation (Exhibit 99.2)?

The investor presentation attached as Exhibit 99.2 contains slides discussing the company’s financial results for the quarter and nine months ended December 31, 2025. Company representatives began using these materials with investors starting February 5, 2026, and may continue using them during the fiscal year.

Are Prestige Consumer Healthcare’s exhibits considered filed or furnished?

The earnings press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) are treated as furnished, not filed. This means they are provided for informational purposes and are not automatically subject to certain liability provisions that apply to documents formally filed under the Exchange Act.

Why did Prestige Consumer Healthcare reference Regulation FD in this report?

The company used this report to share information with all investors at the same time, consistent with Regulation FD. It notes that the investor presentation information should be read along with its other SEC filings and public announcements to fully understand its financial and business position.

How long will Prestige Consumer Healthcare use the February 2026 investor presentation?

The company expects to use the February 5, 2026 investor presentation, in whole or in part and possibly with modifications, during presentations to investors, analysts and others throughout its fiscal year ending March 31, 2026, helping support ongoing discussions of its financial performance.